Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Atazanavir products are in shortage in Canada (3 of 8 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
An antiretroviral medication used to treat HIV infection.
Products affected
3 / 8
In shortage since
Aug 3, 2021
Reports on file
13
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
MYLAN-ATAZANAVIR
300MG · CAPSULE · MYLAN PHARMACEUTICALS ULC
DIN 02456893 · since Aug 3, 2021, no end estimate · Disruption of the manufacture of the drug.
Active shortage
MYLAN-ATAZANAVIR
200MG · CAPSULE · MYLAN PHARMACEUTICALS ULC
DIN 02456885 · since Aug 3, 2021, no end estimate · Disruption of the manufacture of the drug.
Active shortage
MYLAN-ATAZANAVIR
150MG · CAPSULE · MYLAN PHARMACEUTICALS ULC
DIN 02456877 · since Sep 7, 2021, no end estimate · Disruption of the manufacture of the drug.
Discontinued
REYATAZ
200MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02248611
Discontinued
REYATAZ
300MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02294176
To be discontinued
REYATAZ
150MG · CAPSULE · BRISTOL-MYERS SQUIBB CANADA
DIN 02248610
Resolved
TEVA-ATAZANAVIR
200MG · CAPSULE · TEVA CANADA LIMITED
DIN 02443813 · ended Jan 20, 2021 · Disruption of the manufacture of the drug.
Resolved
MYLAN-ATAZANAVIR
200MG · CAPSULE · MYLAN PHARMACEUTICALS ULC
DIN 02456885 · ended Jul 17, 2020 · Delay in shipping of the drug.
Resolved
MYLAN-ATAZANAVIR
150MG · CAPSULE · MYLAN PHARMACEUTICALS ULC
DIN 02456877 · ended Jul 17, 2020 · Delay in shipping of the drug.
Resolved
TEVA-ATAZANAVIR
300MG · CAPSULE · TEVA CANADA LIMITED
DIN 02443821 · ended Jul 22, 2020 · Disruption of the manufacture of the drug.
Resolved
MYLAN-ATAZANAVIR
300MG · CAPSULE · MYLAN PHARMACEUTICALS ULC
DIN 02456893 · ended Jun 25, 2020 · Delay in shipping of the drug.
Resolved
TEVA-ATAZANAVIR
200MG · CAPSULE · TEVA CANADA LIMITED
DIN 02443813 · ended Apr 22, 2020 · Disruption of the manufacture of the drug.
Showing 12 of 13 reports. All reports are on file with Health Canada.
What's happening
Atazanavir is currently affected by 3 active shortage reports filed with Health Canada by MYLAN PHARMACEUTICALS ULC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Atazanavir is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AE).
Recent changes
No changes recorded yet.
Common questions
What is Atazanavir used for?
An antiretroviral medication used to treat HIV infection.
When will Atazanavir be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Atazanavir in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.